X4 Pharmaceuticals, Inc. (XFOR), Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia (CN).
A Phase 3 study of mavorixafor in certain primary CN conditions is underway. Topline data from Phase 3 4WARD study in CN are expected in late 2026.
Mavorixafor is already approved in 2024 for the treatment of WHIM syndrome, a rare genetic disorder.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.